One-Shot gene therapy aims to tame debilitating swelling disorder
NCT ID NCT05120830
Summary
This early-stage study is testing a single injection of an experimental gene therapy called NTLA-2002 in adults with hereditary angioedema (HAE). The main goals are to see if the treatment is safe and if it can reduce the number of painful, unpredictable swelling attacks people experience. Researchers will monitor participants closely for side effects and track how many HAE attacks occur over several months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Campbelltown, Australia
-
Clinical Trial Site
Grenoble, France
-
Clinical Trial Site
Lille, France
-
Clinical Trial Site
Paris, France
-
Clinical Trial Site
Berlin, Germany
-
Clinical Trial Site
Frankfurt, Germany
-
Clinical Trial Site
Amsterdam, Netherlands
-
Clinical Trial Site
Auckland, New Zealand
-
Clinical Trial Site
Cambridge, United Kingdom
Conditions
Explore the condition pages connected to this study.